Shares of Epizyme, Inc. (NASDAQ:EPZM) saw strong trading volume on Thursday . 4,153,413 shares changed hands during mid-day trading, an increase of 514% from the previous session’s volume of 675,952 shares.The stock last traded at $16.05 and had previously closed at $15.95.
Several equities research analysts have commented on the stock. BidaskClub upgraded shares of Epizyme from a “sell” rating to a “hold” rating in a research report on Thursday, August 24th. Leerink Swann reiterated an “outperform” rating and issued a $28.00 price target (down from $31.00) on shares of Epizyme in a research report on Wednesday, August 9th. HC Wainwright reiterated a “buy” rating on shares of Epizyme in a research report on Monday, August 7th. Royal Bank Of Canada set a $20.00 price target on shares of Epizyme and gave the stock a “buy” rating in a research report on Saturday, August 5th. Finally, Zacks Investment Research upgraded shares of Epizyme from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a research report on Tuesday, July 18th. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $23.38.
The company’s market cap is $938.38 million. The stock has a 50 day moving average of $14.77 and a 200-day moving average of $15.13.
Epizyme (NASDAQ:EPZM) last released its earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.08. Epizyme had a negative return on equity of 63.10% and a negative net margin of 1,376.33%. The firm had revenue of $10.00 million for the quarter, compared to analyst estimates of $3.95 million. During the same quarter in the prior year, the firm posted ($0.49) earnings per share. The company’s quarterly revenue was up 2027.7% on a year-over-year basis. Analysts expect that Epizyme, Inc. will post ($2.39) earnings per share for the current year.
In other news, insider Peter Tai-Ching Ho sold 15,000 shares of the firm’s stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of $15.68, for a total transaction of $235,200.00. Following the sale, the insider now owns 22,228 shares of the company’s stock, valued at $348,535.04. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Andrew E. Singer sold 3,024 shares of the firm’s stock in a transaction dated Friday, June 30th. The stock was sold at an average price of $15.50, for a total value of $46,872.00. Following the sale, the chief financial officer now directly owns 40,529 shares in the company, valued at approximately $628,199.50. The disclosure for this sale can be found here. Insiders sold 48,024 shares of company stock worth $706,722 in the last three months. Insiders own 25.20% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in EPZM. Legal & General Group Plc raised its position in shares of Epizyme by 8.9% during the first quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock worth $165,000 after purchasing an additional 795 shares during the period. UBS Asset Management Americas Inc. acquired a new stake in shares of Epizyme during the first quarter worth about $175,000. BB&T Securities LLC acquired a new stake in shares of Epizyme during the second quarter worth about $181,000. Trexquant Investment LP acquired a new stake in shares of Epizyme during the second quarter worth about $184,000. Finally, SG Americas Securities LLC raised its position in shares of Epizyme by 83.3% during the second quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock worth $202,000 after purchasing an additional 6,072 shares during the period. 83.74% of the stock is currently owned by institutional investors.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.